Late cardiotoxicity after treatment for a malignant bone tumor

Medical and Pediatric Oncology
A PostmaW A Kamps

Abstract

Cardiac function was assessed in long-term survivors of malignant bone tumors who were treated according to Rosen's T5 or T10 protocol, both including doxorubicin. Thirty-one patients, age 10-45 years (median age 17.8 years) were evaluated 2.3-14.1 years (median 8.9 years) following completion of treatment. Cumulative doses of doxorubicin were 225-550 mg/m2 (median dose 360). The evaluation consisted of a history, physical examination, electrocardiogram (ECG), signal averaged ECG, 24-hour ambulatory ECG, echocardiography and radionuclide angiography. Eighteen of 31 (58%) patients showed cardiac toxicity, defined as having one or more of the following abnormalities: late potentials, complex ventricular arrhythmias, left ventricular dilation, decreased shortening fraction, or decreased ejection fraction. The incidence of cardiac abnormalities increased with length of follow-up (P< or = .05). No correlation could be demonstrated between cumulative dose of doxorubicin and cardiac status, except for heart rate variability. When adjusted to body surface area, the left ventricular posterior wall thickness (LVPW index) was decreased in all patients. The incidence of doxorubicin-induced cardiotoxicity is high and increases with follow-u...Continue Reading

References

Apr 1, 1977·Cancer·R A MinowJ A Gottlieb
Sep 1, 1992·International Journal of Cardiology·R Y TammingaJ Kievit
Jul 1, 1992·The American Journal of Cardiology·R L LarsenG Barber
Sep 25, 1991·JAMA : the Journal of the American Medical Association·L J SteinherzM L Murphy
Mar 21, 1991·The New England Journal of Medicine·S E LipshultzS P Sanders
Jul 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A C BravermanR T Lee
Jul 1, 1971·Circulation·B Lown, M Wolf
Oct 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C L SchwartzE B Clark

❮ Previous
Next ❯

Citations

Jun 4, 2011·Cardiology Research and Practice·Joy M Fulbright
Dec 17, 2004·Pediatric Blood & Cancer·F Güçlü PinarliSehri Elbeg
Mar 11, 2015·The Lancet Oncology·Saro H ArmenianUNKNOWN International Late Effects of Childhood Cancer Guideline Harmonization Group
May 9, 2009·La Presse médicale·Gerald RoulAri Lieber
Feb 6, 2013·Pediatric Blood & Cancer·Tanya Renae BrownChristopher Fryer
Jul 20, 1999·Current Problems in Pediatrics·C K PhoonM Rutkowski
Jan 16, 1999·Pediatric Clinics of North America·M Grossi
Jan 16, 2002·The Journal of Veterinary Medical Science·A ChugunT Akera
Aug 17, 1999·Cancer Treatment Reviews·M T MeinardiD T Sleijfer
Aug 21, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Melissa M HudsonDavid Rosenthal
May 23, 1998·Journal of Pediatric Oncology Nursing : Official Journal of the Association of Pediatric Oncology Nurses·R B Mosher, B J McCarthy
Aug 1, 2008·Expert Review of Cardiovascular Therapy·Brent Anderson, Douglas B Sawyer
Jun 1, 2017·American Society of Clinical Oncology Educational Book·Emma R LipshultzSteven E Lipshultz
Dec 17, 1998·European Journal of Haematology·T NousiainenJ Hartikainen
Dec 10, 2008·Pediatric Hematology and Oncology·Mehmet KantarSavas Kansoy
May 16, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M T MeinardiW T van der Graaf
Apr 26, 2003·American Journal of Physiology. Heart and Circulatory Physiology·Stéphanie HéonLorraine E Chalifour
Oct 3, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M L HensleyD G Pfister

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.